

Caption for supplementary material

Supplementary Tables

Table S1: Serious adverse events

Table S2: All-cause adverse events

Table S3: Adverse events leading to dose reduction

Table S4: Adverse events leading to treatment discontinuation

Supplementary Figure

Figure S1: Efficacy outcomes and biomarkers in patients who received long-term benefit on erlotinib

*Patients were ordered and numbered by treatment duration (at data cut-off). Next-generation sequencing was undertaken in 3/13 patients with long-term benefit. Mutation data was available for only 1 patient (not annotated in figure).

CR=complete response; PR=partial response; OS=overall survival; SD=stable disease; VS-G=VeriStrat-Good; VS-P=VeriStrat poor; WT=wild-type.